Allogene Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Allogene Therapeutics, Inc. annual/quarterly Share-based Payment Arrangement, Expense history and growth rate from Q2 2018 to Q3 2024.
  • Allogene Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $13.4M, a 13% decline year-over-year.
  • Allogene Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $51.7M, a 21.5% decline from 2023.
  • Allogene Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $66M, a 21.1% decline from 2022.
  • Allogene Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $83.6M, a 3.47% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $13.4M -$2M -13% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q1 2024 $60.8M $13.6M -$5.2M -27.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-07
Q4 2023 $66M $15.2M -$2.1M -12.1% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-13
Q3 2023 $68M $15.4M -$5.75M -27.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $73.8M $16.6M -$6.29M -27.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $80.1M $18.8M -$3.52M -15.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $83.6M $17.2M -$4.77M -21.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $88.4M $21.1M +$292K +1.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $88.1M $22.9M +$1.76M +8.31% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $86.3M $22.3M +$5.52M +32.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $80.8M $22M +$5.53M +33.5% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 $75.3M $20.9M +$3.03M +17% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $72.2M $21.1M +$4.36M +26% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $67.9M $16.8M +$2.58M +18.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $65.3M $16.5M +$2.62M +18.9% Oct 1, 2020 Dec 31, 2020 10-K/A 2024-03-14
Q3 2020 $62.7M $17.8M +$4.99M +38.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $57.7M $16.8M +$5.28M +46% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $52.4M $14.2M +$6.35M +80.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $46.1M $13.9M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-23
Q3 2019 $12.8M +$8.2M +177% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $11.5M +$3.43M +42.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $7.87M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q3 2018 $4.64M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $8.06M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.